Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:

P631

Long-term outcome of colorectal cancer in Crohn’s and ulcerative colitis: a comparative study

Authors:

S. Scaringi*1, C. Di Martino1, F. Giudici1, D. Zambonin1, F. Tonelli2, F. Ficari1, P. Bechi1

1Careggi University Hospital, Surgery and Translational Medicine, Florence, Italy, 2University of Florence, Florence, Italy

P632

Serum vedolizumab assay at week 6 predicts sustained clinical remission and lack of recourse to optimisation in inflammatory bowel disease

Authors:

N. Williet*1, s. Paul2, E. Del tedesco1, J. M. Phelip1, X. Roblin*1

1CHU Saint Etienne, Saint Etienne, France, 2University of Saint Etienne, Immunology, Saint Etienne, France

P633

Quality of life in paediatric inflammatory bowel disease patients in a self-administered telemedicine randomised clinical study

Authors:

K. Carlsen*1, 2, C. Jakobsen2, L. F. Hansen2, A. Paerregaard2, T. Kallemose3, L. B. Riis4, P.S. Munkholm5, V. Wewer2

1Hvidovre Hospital, Paediatric, Hvidovre, Denmark, 2Hvidovre Hospital, Department of Paediatrics, Hvidovre, Denmark, 3Hvidovre Hospital, Clinical Research Centre and Department of Orthopaedic, Hvidovre, Denmark, 4Herlev Hospital, Department of Pathology, Herlev, Denmark, 5North Zealand Hospital, Department of Gastroenterology, Frederikssund, Denmark

P634

Escalation of IFX therapy in paediatric versus adult inflammatory bowel disease patients: results from a prospective single-centre cohort study

Authors:

D. Winter*1, C. van der Woude2, J. Escher1

1Children’s Hospital Erasmus MC Sophia, Department of Paediatric Gastroenterology, Rotterdam, Netherlands, 2Erasmus Medical Centre, Department of Gastroenterology and Hepatology, Rotterdam, Netherlands

P635

Personalised prophylactic use of thiopurines prevented surgical recurrence in patients with Crohn’s disease after intestinal resection

Authors:

X. Luo, R. Mao, B. Chen, Y. He, Z. Zeng, M. Chen*

The First Affiliated Hospital, Sun Yat-sen University, Department of Gastroenterology, Guangzhou, China

P636

Patient support programme is well accepted and could help adherence in inflammatory bowel disease patients

Authors:

G. Lorenzon*1, M. G. Vettorato1, E. De Marchi1, O. Bartolo1, R. Caccaro1, F. Cavallin2, G. Girardin1, A. Rigo1, F. Simonetti1, E. V. Savarino1, G. C. Sturniolo1, R. D’Incà1

1University of Padua, Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy, Padua, Italy, 2University of Padua, Surgical Oncology Unit, Regional Centre for Oesophageal Disease, Veneto Institute of Oncology, Padua, Italy, Padua, Italy

P637

Pharmacokinetics of golimumab in patients with moderate-to-severe ulcerative colitis

Authors:

S. Berends*1, A. Strik2, P. van Egmond1, H. Brandse2, R. Mathôt1, G. D’Haens2, M. Löwenberg2

1Academic Medical Centre (AMC), Hospital Pharmacy, Amsterdam, Netherlands, 2Academic Medical Centre (AMC), Gastroenterology, Amsterdam, Netherlands

P638

Assessment of IMPACT III emotional and social functioning domain scores in adalimumab-treated paediatric patients with Crohn’s disease

Authors:

A. Grant*1, A. Otley1, 2, J. Escher3, J. S. Hyams4, J.-F. Maa5, G. Alperovich5, A. Lazar6, A. M. Robinson5, A. W. Wang5, S. Eichner5

1IWK Health Centre, Nova Scotia, Canada, 2Dalhousie University, Nova Scotia, Canada, 3Erasmus MC Sophia Children’s Hospital, Rotterdam, Netherlands, 4Connecticut Children’s Medical Centre, Hartford, Connecticut, United States, 5AbbVie Inc, North Chicago, Illinois, United States, 6AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany

P639

Faecal microbiota transplantation as a rescue therapy for steroid-dependent and/or non-responsive patients with ulcerative colitis: a pilot study.

Authors:

T. Karakan*, M. İbiş, M. Cindoruk, Z. G. Sargin, N. Alizadeh

GAZI UNIVERSITY, GASTROENTEROLOGY, ANKARA, Turkey

P640

Co-detection of infliximab and antibodies in an ECLIA assay amongst IBD patients treated with infliximab

Authors:

R. Colman*1, 2, D. Rubin1

1University of Chicago Medicine Inflammatory Bowel Disease Centre, Chicago, Illinois, United States, 2St Barnabas Hospital, Pediatrics, Bronx, New York, United States

P641

Vitamin D levels during remission are associated with the risk of clinical relapse in patients with ulcerative colitis

Authors:

J. M. Gubatan*, S. Mitsuhashi, T. Zenlea, L. Rosenberg, S. Robson, A. Moss

Beth Israel Deaconess Medical Centre, Harvard Medical School, Division of Gastroenterology, Department of Medicine, Boston, Massachusetts, United States

P642

Adalimumab and postoperative complications of intestinal resections in Crohn’s disease: a case-matched study

Authors:

P. G. Kotze*1, B. Saab1, M. P. Saab1, L. V. Pinheiro2, M. L. S. Ayrizono2, C. A. R. Martinez2, D. O. Magro2, M. Olandoski3, L. M. S. Kotze1, C. S. R. Coy2

1Catholic University of Paraná, Colorectal Surgery Unit - Cajuru University Hospital, Curitiba, Brazil, 2Campinas State University (UNICAMP), Colorectal Surgery department, Campinas, Brazil, 3Catholic University of Parana, Department of Statistics, Curitiba, Brazil

P643

Safety and efficacy of daily granulocyte and monocyte adsorptive apheresis in 50 consecutive patients with active ulcerative colitis: a prospective study

Authors:

T. Yamamoto*, T. Shimoyama, S. Umegae, K. Matsumoto

Yokkaichi Hazu Medical Centre, Inflammatory Bowel Disease Centre, Yokkaichi, Japan

P644

Influence of anti-tumour necrosis factor-α therapy on pregnancy-related outcomes and immunity of the children in women with inflammatory bowel disease

Authors:

K. E. Lee*1, S.-A. Jung1, S. H. Park2, C. M. Moon1, S. Y. Shim3, E. S. Kim4, S. J. Cho3, S.-E. Kim1, K. B. Cho4, S.-K. Yang2

1Ewha Woman’s University School of Medicine, Department of Internal Medicine, Seoul, South Korea, 2University of Ulsan College of Medicine, Department of Internal Medicine, Seoul, South Korea, 3Ewha Woman’s University School of Medicine, Department of Paediatrics, Seoul, South Korea, 4Keimyung University School of Medicine, Department of Internal Medicine, Daegu, South Korea

P645

Efficacy and safety of biosimilar of infliximab in rescue therapy in adult patients with severe ulcerative colitis

Authors:

M. Kaniewska*1, G. Rydzewska1, 2

1Central Clinical Hospital of the Ministry of Interior, Department of Gastroenterology, Warsaw, Poland, 2Faculty of Medicine and Health Science, Jan Kochanowski University, Kielce, Poland

P646

Has there been a change in the treatment of Crohn’s disease over the years? Comparison of 2 prospective cohorts in a tertiary referral centre

Authors:

O. Icht*1, H. Yanai1, Y. Ron1, G. Rosner1, A. Yaron2, A. Waizbard3, S. Fishman1, I. Dotan1

1IBD Centre, Department of Gastroenterology and Liver Diseases, Tel Aviv Sourasky Medical Centre, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, 2Pediatric Gastroenterology Unit, Dana’s Children Hospital, Tel Aviv Sourasky Medical Centre, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, 3Department of Gastroenterology, Laniado medical Centre, Netanya, Israel

P647

Efficacy and safety of endoscopic balloon dilation for symptomatic intestinal Crohn’s disease strictures

Authors:

A. Casadei, E. Cavargini, L. Samperi, D. Valpiani*, I. Manzi, E. Ricci

U.O. Gastroenterologia ed Endoscopia digestiva Ospedale ‘G.B. Morgagni’, Dipartimento di Medicina specialistica, Forlì, Italy

P648

Impact of high-dose vitamin D3 supplementation in treatment of Crohn’s disease in remission: a randomised double-blind controlled study

Authors:

N. Narula*, M. Cooray, R. Anglin, Z. Muqtadir, A. Narula, J. Marshall

McMaster University, Gastroenterology, Hamilton, ON, Canada

P649

Crohn’s disease patients with high body mass index present more frequent and rapid loss of response to infliximab

Authors:

L. Guerbau*, R. Gerard, N. Duveau, P. Desreumaux, M. Boualit, J. Branche, V. Maunoury, L. Libier, S. Cattan, C. Gower-Rousseau, A. Cotteau-Leroy, M. Nachury, B. Pariente

Centre Hospitalier Universitaire de Lille, Lille, France

P650

Patient perceptions of food-based dietary treatment of Crohn’s disease: a survey of paediatric patients previously treated with exclusive enteral nutrition

Authors:

V. Svolos*1, K. Gerasimidis1, V. Garrick2, L. Curtis2, J. Hay2, E. Buchanan2, R. Russell2, R. Hansen2

1Human Nutrition, School of Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow Royal Infirmary, Glasgow, United Kingdom, 2Department of Paediatric Gastroenterology, Hepatology and Nutrition, Royal Hospital for Children, Glasgow, United Kingdom